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Abstract: Several studies have identified specific signalling functions for inositol polyphosphates
(IPs) in different cell types and have led to the accumulation of new information regarding their
cellular roles as well as new insights into their cellular production. These studies have revealed
that interaction of IPs with several proteins is critical for stabilization of protein complexes and for
modulation of enzymatic activity. This has not only revealed their importance in regulation of several
cellular processes but it has also highlighted the possibility of new pharmacological interventions in
multiple diseases, including cancer. In this review, we describe some of the intracellular roles of IPs
and we discuss the pharmacological opportunities that modulation of IPs levels can provide.
Keywords: inositol phosphates; cell signaling; experimental pharmacology; pleckstrin homology
domain; inositol 1,3,4,5,6-pentakisphosphate; inositol 1,2,3,4,5,6-hexakisphosphate
1. Introduction
The water-soluble inositol polyphosphates (IPs) and the inositol lipids phosphoinositides (PIs)
are all derivatives of inositol (Ins), especially myo-Ins, the most common isomeric form (Figure 1) [1].
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Figure 1. Schematic representation of myo-inositol (Ins) and its derivative phosphatidylinositol (PtdIns),
showing the attached diacylglycerol linked to the myo-Ins head group via a phosphodiester bond (in red).
Differential phosphorylation of myo-Ins or PtdIns generates the family of inositol polyphosphates (IPs)
and phosphoinositides (PIs), respectively.
Myo-Ins can derive from glucose-6-phosphate in a process involving its cyclization to Inositol
3-phosphate (Ins3P) or Inositol 1-phosphate (Ins1P) (catalyzed by myo-inositol-3-phosphate synthase
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or myo-inositol-1-phosphate synthase, respectively), followed by dephosphorylation, catalyzed by
inositol monophosphatase. Alternatively, Ins1P or Inositol 4-phosphate (Ins4P) can derive from
dephosphorylation of Inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) [1]. Myo-Ins possesses one axial and five
equatorial hydroxyl groups whose differential phosphorylation leads to distinct inositol species (IPs).
In fact, over thirty distinct IPs have been described in mammalian cells so far [2], including inositol
pyrophosphates (PP-IPs), pyrophosphorylated IPs that derive from further phosphorylation of the “fully
phosphorylated” Inositol 1,2,3,4,5,6-hexakisphosphate (InsP6) through formation of highly energetic
phosphoanhydride bonds (pyrophosphates) at specific positions. Several well-known kinases and
phosphatases catalyze the interconversion of IPs, with some showing specificity for selective species,
such as Inositol pentakisphosphate 2-kinase (IPPK) which converts Inositol 1,3,4,5,6-pentakisphosphate
(InsP5) into InsP6, and others showing a broader specificity towards different species, such as
Inositol polyphosphate multikinase (IPMK). IPMK is essential for the synthesis of both Inositol
1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4) and Inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) as well as
InsP5 [3–6]. IPMK can also phosphorylate Inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P4) [6]. IPMK
is a key enzyme for the synthesis of the higher phosphorylated IPs, as demonstrated by the impaired
synthesis of InsP5 and InsP6 detected in mouse embryonic fibroblasts (MEFs) deficient for the enzyme [7].
Furthermore, MEFs lacking all the three Inositol 1,4,5-trisphosphate 3-kinases (ITPKA, ITPKB and
ITPKC) that specifically phosphorylate the 3-phosphate position of the inositol ring still produce
InsP5 and InsP6, confirming that the main synthetic route of these IPs is through IPMK [8]. However,
recent studies suggest that ITPKs regulate InsP6 synthesis through an alternative route in mammalian
cells [9] and that ITPKA plays a critical role in maintaining InsP6 cellular levels in mammalian colorectal
cancer cell lines [10]. Many inositol products play a crucial role in eukaryotic cells and are involved in a
wide number of biochemical functions. This review covers some examples of the processes regulated by
IPs and mentions some of the potential pharmacological opportunities arising from modulation of IPs
levels. The many roles of PP-IPs have been covered elsewhere in this special issue [11].
2. Ins(1,4,5)P3, a Bona Fide Second Messenger
Ins(1,4,5)P3 was the first IP to be identified as a “second messenger” more than 35 years ago [12,13]
and its identification as a key regulator of Ca2+ release from intracellular stores sparked much interest on
the role of inositol-derived molecules in signal transduction. Specifically, Ins(1,4,5)P3 derives from the
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), which is catalyzed by members of
the family of phospholipases C (PLC). Upon cellular stimulation and PLCs activation, the accumulated
Ins(1,4,5)P3 can bind to Ins(1,4,5)P3 receptors which are expressed in most animal cells and are
Ca2+ channels located on intracellular organelles such as the endoplasmic reticulum (ER) and Golgi
apparatus. Such binding mediates Ca2+ release from intracellular stores, resulting in Ca2+ accumulation
in the cytosol and in organelles such as mitochondria and lysosomes. A schematic representation
of the Ins(1,4,5)P3-mediated Ca2+ release following activation of G protein-coupled receptors and of
some members of the PLC family is depicted in Figure 2. The resulting decrease in ER luminal Ca2+
concentration also triggers stromal interaction molecule 1, which then amasses at ER–plasma membrane
(PM) junctions and opens Orai1, a hexameric Ca2+ channel in the PM [14,15], causing store-operated
Ca2+ entry. Through these Ins(1,4,5)P3-mediated mechanisms, many extracellular stimuli induce
redistribution of Ca2+ from the ER to the cytosol or other organelles as well as extracellular Ca2+
entry [16]. Ca2+ regulates a multitude of intracellular processes including transcription, apoptosis,
motility, excitability and exocytosis, mainly through modulation of protein conformations and
charge [17]. Together with its direct role in signalling, Ins(1,4,5)P3 serves as a precursor for the synthesis
of several highly phosphorylated IPs, including Ins(1,3,4,5)P4, InsP5 and InsP6. Importantly, a recent
study has identified additional mechanisms that can lead to synthesis of higher phosphorylated IPs,
independently from the Ins(1,4,5)P3 pool derived from the lipid PtdIns(4,5)P2. Such an alternative
route involves phosphorylation of inositol monophosphates (such as the previously mentioned Ins3P
and Ins1P) by the kinase inositol tetrakisphosphate 1-kinase 1 and it depends on the metabolic status of
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the cells [9]. Whether the higher phosphorylated IPs can all be strictly considered “second messengers”
has somehow been a matter of debate [9]. Nonetheless, their importance in regulation of a multitude
of cellular processes is unquestionable.
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release. GPCR, G protein-coupled receptor; IP3, Ins(1,4,5)P3; Ca++, calcium; ER, endoplasmic reticulum;
IP3R, Ins(1,4,5)P3 receptor; DAG, diacylglycerol; PIP2, PtdIns(4,5) 2.
3. Intracellular Processes Regulated by IPs Binding to Proteins
key feature of IPs is their ability to bind to proteins and either contribute to aintain their
structural fold or pro ote/stabilize their assembly into complexes or contribute to their activation,
in the case of enzymes. Such binding properties are responsible for most of the intracellular roles
that have been attributed to IPs. Indeed, IPs have been found to be involved in regulation of a
vast array of very different intracellular processes. Just to mention an example of the diversity of
intracellular roles that IPs can have, InsP6 has been implicated, amongst many other processes
that we will mention later, in: (i) regulation of the activity of the RNA editing enzyme adenosine
deaminase that act on RNA (ADAR)2 as well as adenosine deaminases that act on transfer RNA
(ADAT)1 [18]; (ii) activation of Bruton’s tyrosine kinase, a Tec-family tyrosine kinase that is essential
for B-cell function [19]; (iii) regulation of casein kinase 2 [20], a ubiquitous protein kinase that can
phosphorylate over 300 proteins involved in cell growth, development and several other cellular
functions; (iv) allosteric regulation of Yersinia outer-protein J effectors, important to control their
acetyltransferase activity [21]; (v) ubiquitylation, through regulation of the activity state of cullin-RING
E3 ubiquitin ligases [22]; (vi) crotonylation, as indicated by data demonstrating that addition of InsP6
to the complex histone deacetylase (HDAC)1/CoREST/Lysine specific demethylase 1 increased its
initial rate of decrotonylation by 1.8-fold [23].
In fact, IPs have been detected in several X-ray crystal structures and this suggests their involvement
in many cellular processes [24]. As additional evidence of these interactions accumulates, the variety
of cellular processes that relies on the correct balance between different IPs species is becoming more
evident. Few examples of some of the first cellular functions that were attributed to IPs together ith
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some of the most recently identified will be mentioned here. Attention is focused on processes that
can provide examples of the rationale behind the design of potential therapeutic strategies based on
exploitation of the role of IPs.
3.1. Endo and Exocytosis
The identification of proteins able to bind to InsP6, such as clathrin assembly proteins (AP)-2 [25]
and AP-3 [26] and arrestin [27] suggested very early a role for this IP in endocytosis and exocytosis.
Indeed, InsP6 was proposed to be involved in the regulation of both processes in pancreatic β cells,
where it appeared to be the most abundant IP [28]. Specifically, InsP6 was shown to regulate insulin
exocytosis by enhancing the activity of the voltage-dependent Ca2+ channels through deactivation of
Serine/Threonine protein phosphatases and activation of Serine/Threonine kinases [28,29]. In addition,
InsP6 was also reported to be involved in the regulation of calcineurin-dependent endocytosis in β
cells [30]. Over the years, roles for different IPs, in particular PP-IPs, in the complex process of insulin
secretion have been described more precisely [31,32]. A wider role for InsP6 in regulation of endocytosis
was further indicated by data supporting its involvement in regulation of this process in synaptic vesicle.
This was suggested by the identification of its role in phosphorylation of a protein kinase responsible
for regulation of the synaptic vesicle-associated protein pacsin/syndapin I and the demonstration that
such InsP6-regulated phosphorylation increased the interaction between dynamin and pacsin/syndapin
I [33]. Importantly, a specific role for InsP6 (and isomers of the PP-IP InsP7) was reported in this study,
with no phosphorylation detected using lower IPs, in particular InsP3 or InsP4 [33].
3.2. Nuclear Functions
Ins(1,4,5,6)P4 has emerged as a key regulator of some members of the family of class I HDACs,
enzymes that regulate lysine acetylation in histone tails and are involved in epigenetic regulation
of genes [34]. The role of Ins(1,4,5,6)P4 was first suggested by its presence in the crystal structure
of HDAC3 and its co-repressor silencing mediator of retinoic acid and thyroid hormone receptor
(SMRT), specifically in a binding pocket at the interface between the enzyme and the co-repressor [35].
Later studies corroborated that the inositol phosphate-binding pocket was present in other class I
HDAC co-repressor complexes, and, indeed, it was reported that Ins(1,4,5,6)P4 enhances the deacetylase
activity of both the HDAC3:SMRT and HDAC1:SMRT complexes [36]. The stereochemical requirement
for binding and activation by IPs has also been described [37]. Furthermore, mutations that abolish
InsP4 binding decrease the activity of HDAC1/2 in vivo [38]. These data indicate a role for Ins(1,4,5,6)P4
in histone acetylation and chromatin condensation and contribute to the growing interest around the
role of IPs and PIs in epigenetic regulation.
A role for InsP6 in the nucleus has been suggested by many lines of evidence, including the
identification of a well-ordered InsP6 molecule in the crystal structure of sister chromatid cohesion
protein Pds5 homolog B (Pds5B), a subunit of the cohesin complex, which controls transcription,
chromosome segregation and DNA repair [39]. Additional studies have indicated that InsP6 has a
role in DNA repair, in particular non-homologous end-joining mediated by DNA-dependent protein
kinase [40] and nuclear mRNA export [41], acting together with nucleoporin Gle1 [42,43]. A role for
InsP5 and InsP6 in chromatin remodelling was also reported [44,45].
3.3. Platelet Aggregation
A recent study has reported the increase of InsP6 in platelets upon stimulation with thrombin,
collagen I and ADP [46]. Importantly, this study has revealed a role for InsP6 in regulation of platelet
aggregate size, in a mechanism involving its interaction with fibrinogen. Although previous evidence
identified both InsP5 and InsP6 as binding partners of fibrinogen [47], InsP5 did not have a role in
regulation of aggregation, which appeared specific for InsP6 [46]. The authors suggested a role for
InsP6 in supporting and stabilizing the crosslinking between fibrinogen and platelets, identifying this
IP as a novel potential player in regulation of platelet functions [46].
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3.4. Reactive Oxygen Species (ROS) Formation and Drug Sensitivity
A very recent study reported that InsP4 selectively binds to the enzyme NADPH oxidase 4 (NOX4)
which is important for ROS generation [48]. Such a direct interaction competes with NADPH binding to
NOX4 and inhibits the enzyme, resulting in reduced ROS production. Importantly, the authors showed
that downregulation of ITPKB, sensitized cisplatin-resistant cancer cells to cisplatin treatment both
in vitro and in vivo. This was likely due to the reduced levels of InsP4, which would result in increased
ROS production and therefore increased cisplatin-induced ROS production [48]. Consistent with
this, the authors reported that expression of ITPKB and cisplatin resistance positively correlated in
22 human cancer cell lines and 13 patient-derived xenograft tumours of head and neck squamous cell
carcinoma (HNSCC), lung cancer and ovarian cancer. In addition, it was shown that expression of the
enzyme was higher in primary tumours from HNSCC patients who had recurrent disease compared
with tumours from responsive patients [48]. The observation that chemical inhibition of ITPKB also
sensitized cells to cisplatin treatment both in vitro and in vivo confirms how manipulation of IPs levels
can have an important therapeutic value [49].
3.5. Viral Replication
Several lines of evidence indicate that InsP6 plays a crucial role during HIV-1 infection,
being involved in some of the several capsid transformations that occur during viral replication.
Specifically, it has been reported that HIV-1 recruits InsP6 into virions using two Lysine rings in its
immature hexamers [50] and that InsP6 in turn promotes the assembly and maturation of the mature
capsid lattice [51–53]. Furthermore, binding of InsP6 increases HIV-1 capsid stability from minutes to
hours, enabling freshly synthesized DNA to gather inside the capsid during reverse transcription [54].
These data indicate that InsP6 is important in HIV-1 assembly and during viral entry by stabilizing the
capsid while moving towards the nucleus, making it a critical cofactor for HIV replication (Figure 3).
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with this, a recent study revealed that, in the absence of InsP6, as achieved upon genetic knockout of
IPMK and IPPK, HIV-1 packages InsP5 and it can substitute InsP5 for InsP6 during viral production
without affecting its infectivity [50]. Indeed, InsP5 was found to be able to stimulate immature HIV-1
assembly in vitro, although less efficiently that InsP6 [50,51,54]. A very recent study has demonstrated
that the almost complete ablation of both InsP6 and InsP5 induced a 1000-fold reduction (i.e., an almost
abrogation) in the production of HIV-1 infectious particle and virus release, establishing an absolute
requirement for these IPs in HIV-1 viral production [55]. Furthermore, the authors demonstrated
that ablation of InsP6 and InsP5 in viral target cells did not affect permissivity to HIV-1 infection [55].
Importantly, recent evidence suggests a conserved role for InsP6 in lentiviral assembly, as indicated
by its ability to stimulate the in vitro assembly of immature particles of many other retroviruses in
the lentivirus genus [56]. On the other hand, ablation of IPPK only modestly reduced the production
of infectious particles by other retroviruses, such as a gammaretrovirus, a betaretrovirus and two
non-primate lentiviruses. This study in particular demonstrated that only the primate (macaque)
lentivirus simian immunodeficiency virus displayed a similar dependence on InsP6/InsP5 as HIV-1 [55].
4. Exploiting the Binding Properties of IPs for Therapeutic Purposes
4.1. Exogenous IPs
Until now, the therapeutic potential of IPs has been mainly tested through administration of
exogenous IPs. In some cases, this strategy aims to inhibit PIs-dependent signaling pathways through
competition between exogenous IPs and endogenous PIs towards same protein domains. The best
example of this is provided by proteins containing pleckstrin homology (PH) domains, protein modules
that can bind to IPs and PIs [57–59]. Twenty years ago, we hypothesized that water soluble IPs could
be delivered intracellularly to compete with PIs for PH domain binding and therefore they could
inhibit activation of proteins that rely on PIs/PH domain interaction [2]. Over the following years,
we and others demonstrated that this strategy was correct and it held potential therapeutic value.
Work in our lab was mostly focused on Akt PH domain, whose interaction with phosphatidylinositol
3,4,5-trisphosphate (PtdIns(3,4,5)P3) is critical for its translocation to the plasma membrane and
enzymatic activation. (Figure 4).
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As it was known that InsP5 and, to a slightly lesser extent, Ins(1,4,5,6)P4, were also able to bind
Akt PH domain [57], we hypothesized that these IPs could compete with PtdIns(3,4,5)P3 for Akt PH
domain binding, resulting in inhibition of Akt translocation to the plasma membrane. A schematic
representation of the mechanism of Akt activation upon growth factors-mediated activation of receptor
Tyrosine kinases as well as the inhibitory role of exogenous IPs (in particular of InsP5) are shown in
Figure 4. Indeed, supporting our hypothesis of a potential competition between the two groups of
compounds, we observed that plasma membrane translocation of a Green fluorescent protein-tagged
Akt PH domain was inhibited by exogenous Ins(1,4,5,6)P4 [60]. Later additional evidence of such
an inhibition appeared, including data showing that a cell permeant Ins(1,3,4,5)P4 was able to
inhibit a receptor-dependent plasma membrane translocation of AKT PH domain in neutrophils [61].
More important, impairment of Akt plasma membrane translocation resulted in inhibition of its
activation, as indicated by our subsequent studies showing that exogenously added InsP5 inhibited
phosphorylation of Akt in ovarian cancer line SKOV-3 cells [62], in PTEN-/- embryonic stem cells [62],
in human umbilical vein endothelial cells (HUVEC) activated with basic fibroblast growth factor
(FGF-2) [63] and in dissected tumours from a xenograft model of SKOV-3 cells [63]. Notably, our studies
confirmed that the IPs-mediated inhibition of Akt phosphorylation was able to affect Akt-dependent
cellular processes. Specifically, the addition of exogenous Ins(1,4,5,6)P4 and InsP5 resulted in inhibition
of proliferation/growth of breast cancer cell line MCF7, small cell lung cancer cell line H69 and
SKOV-3 cells [60]. Furthermore, InsP5 induced apoptosis in H69 cells and SKOV-3 cells [62] and
inhibited FGF-2-induced cell survival, cell migration and capillary tube formation in HUVECs as well
as inhibiting angiogenic response in vivo [63]. Additional evidence of the anti-angiogenic properties
of InsP5 has been provided by a recent study reporting that InsP5 can also inhibit vascular endothelial
growth factor production by fibroblasts and neural cells in a mechanism involving degradation of
hypoxia inducible factor 1α [64]. The definite demonstration that such a strategy could represent an
important potential therapeutic strategy came from the observation that InsP5 reduced tumour growth
in a xenograft model of SKOV-3 cells [63]. Interestingly, in this experimental setting, treatment with
InsP6 did not reduce tumour growth or Akt activation in dissected tumours [63].
The potential beneficial effects of exogenous IPs in cancer might go beyond their inhibition
of PIs-mediated processes. For instance, InsP6 has been reported to have anti-cancer activity in
several in vitro and in vivo models [65], including prostate [66–68], breast [69,70], bladder [71] and
colon [72,73] cancer. Some very preliminary clinical results are also appearing [65]. Whether InsP6 exerts
its anti-cancer activity by interfering with PIs-mediated activation of proteins is not established, as it has
been reported that its inhibition of cancer cell proliferation, cancer cell survival and metastasis [64,74,75]
is a result of inhibition of several pathways, including the phosphoinositide 3-kinase [PI3K)/Akt
pathway [67,73,76]. The impact of InsP6 can be very diverse: recently, for instance, its involvement
in regulation of microRNA levels, in particular miR-155, in human colon cancer cells has also been
reported [77], suggesting additional mechanisms by which this IP might exert its anti-cancer activity.
Indeed, InsP6 therapeutic potential has been mainly related to its anti-oxidant properties and its
ability to oppose many carcinogens [65]. It must be noted that concentrations of exogenously added
InsP6 reported to have anti-cancer activity in vitro were usually in the millimolar range (1–5 mM),
i.e., concentrations that can induce metals chelation and changes in the pH in cellular medium.
To avoid this problem, a recent study has reported the synthesis of a prodrug of InsP6 which retains
the pro-apoptotic activity in vitro as well as anti-cancer activity in vivo in a mouse model of adult
T-cell leukemia [78]. Whether the anti-cancer activity is due to InsP6 itself or to its rapid conversion to
other IPs, namely InsP5 and InsP4, remains a matter of debate. Analysis of the IPs in extracts of intact
HeLa cells incubated with 3H-InsP6 revealed that 3H-InsP3, 3H-InsP4 and 3H-InsP5 accumulated inside
the cells, confirming that internalized InsP6 was dephosphorylated into lower forms [79]. Moreover,
these authors reported that both Ins(1,4,5,6)P4 and InsP5 were more active than InsP6 in inducing
apoptosis [79]. Consistent with this, recent evidence indicated that InsP6 derivatives, resulting from
partial degradation of ingested InsP6 by phytase into hydrolysates, also possess anti-cancer activity.
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For instance, it has been reported that partially degraded InsP6 inhibited proliferation of HCT116 colon
carcinoma cells [80]. Similarly, a study demonstrated that InsP6 hydrolysates inhibited proliferation
of the colorectal cancer cell line SW620, with evidence suggesting that InsP4 and InsP5 were the
likely primary constituents of the hydrolysates responsible for the anti-proliferative activity via
Akt inhibition [72]. In contrast to InsP6, we found that exogenous InsP5 not only was quickly and
systematically internalized by cells but it was also converted slowly into different metabolites [63],
supporting the conclusion that its anti-tumour effects were due to its activity and were not mediated
by conversion to different phosphorylated forms.
Potential beneficial effects of exogenous IPs have also been explored in other diseases including
diabetes [81], which, possibly, is not surprising considering that IPs and PP-IPs have been involved in
insulin secretion, as previously mentioned.
4.2. Interfering with IPs/Proteins Binding
As we discussed above, many of the cellular roles of IPs depend on their ability to bind proteins
and modulate their assembly into complexes or their activation. This raises the interesting possibility
of inhibiting selective cellular processes by modulating intracellular levels of IPs through blockade of
one of the enzymes responsible for their interchange or by developing compounds that might interfere
with the selective IPs/proteins binding. For instance, small molecules might be designed to interfere
with the recruitment of InsP6 in the immature hexamers or possibly compete with InsP6 and therefore
they might block HIV viral particles production. Similar compounds might interfere with InsP6 to
fibrinogen and therefore possibly be beneficial to destabilize thrombi, as hypothesized recently [46].
However, even though this strategy is potentially interesting, possible limitations need to be taken
into accountthe use of IPs as novel therapeutics should consider the variety of roles that they have in
cell homeostasis, such as insulin signaling and nuclear processes [82], that could potentially generate
off-target effects and hence side effects.
5. Conclusions
The family of IPs has been implicated in a multitude of intracellular functions and new evidence
constantly appears identifying their contribution to additional processes. Such a variety and versatility
of roles mean that several opportunities exist to exploit these molecules from a therapeutic point of
view, either by delivering IPs and/or their analogues intracellularly or by manipulating the enzymes
that control their interchanges or by interfering with their interaction with their effector proteins.
In this respect, additional studies to shed light into the specific mechanisms of interaction between IPs
and their effector proteins (such as X-ray crystal structure and modelling) might provide important
information to design novel strategies to interfere with their cellular processes.
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